Company Overview and News

2
Will Balanced Capital Deployment Aid Domtar's (UFS) Growth?

2018-08-11 zacks
On Aug 9, we issued an updated research report on Domtar Corporation (UFS - Free Report) . The company is poised to gain from its balanced capital-deployment approach. Further, improvement in paper shipment, reduced overhead spending, new customer wins and price increases will drive growth. Let’s illustrate these growth factors in detail. Domtar to Grow on Balanced Capital-Deployment Approach Domtar will continue to pursue a balanced approach toward capital deployment while focusing on investing in innovation.
SVCBF GJV SVCBY SEOFF NWS NWSA UFS SEOAY SEOJF

3
WestRock (WRK) on Buyout Spree, Set to Acquire Schluter

2018-08-09 zacks
WestRock Company (WRK - Free Report) recently entered into an agreement to acquire Schlüter Print Pharma Packaging — a German-based supplier of a full range of leaflets and booklets. Financial terms of the transaction have not been disclosed yet. Why Schlüter? Schlüter utilizes UV flexographic printing technology to produce film solutions in its primary packaging area. Its secondary packaging products include folding boxes and booklets, such as pharmaceutical mini-brochures.
GD SEOFF ZTO UFS SEOAY WRK SEOJF

 
Danske Bank A/S laskee liikkeeseen 39 warranttisarjaa 8.8.2018

2018-08-07 globenewswire
Danske Bank A/S:llä on Irlannin keskuspankin 18.6.2018 hyväksymä warrantti- ja sertifikaattiohjelmaesite, jota on täydennetty 24.7.2018 julkistetulla ohjelmaesitteen täydennyksellä.
SEOFF KNYJF OUTFF CYJBY FOJCF DNSKY NTOIF DNKEY YITYF YITYY OUTKY FOJCY CYJBF SEOAY DNSKF KNYJY SEOJF NTOIY

2
Domtar's (UFS) Q2 Earnings Miss, Revenues Beat Estimates

2018-08-03 zacks
Domtar Corporation (UFS - Free Report) reported second-quarter 2018 adjusted earnings of 65 cents per share, which increased 6.6% year over year. However, adjusted earnings missed the Zacks Consensus Estimate of 77 cents. Including one-time items, Domtar posted earnings per share of 68 cents in the quarter compared with 61 cents reported in the year-ago quarter. Consolidated sales totaled $1,353 million compared with $1,221 million in the year-earlier quarter, outpacing the Zacks Consensus Estimate of $1,323 million.
SVCBF SVCBY SEOFF UFS SEOAY SEOJF

 
Stora Enso Oyj ADR 2018 Q2 - Results - Earnings Call Slides

2018-07-20 seekingalpha
The following slide deck was published by Stora Enso Oyj ADR in conjunction with their 2018 Q2 earnings call.
SEOAY SEOJF

 
Stora Enso shares drop 10% after half-year financial report

2018-07-20 marketwatch
Stora Enso Oyj engages in the manufacturing and marketing of newsprint, book paper, magazine paper, fine paper, consumer board, industrial packaging, and wood products. It operates through the following divisions: Consumer Board, Packaging Solutions, Biomaterials, Wood Products, and Paper. The Consumer Board division develops and provides consumer packaging boards for printing and packaging applications.
SEOFF SEOAY SEOJF

 
International Paper Drops Buyout Proposal for Smurfit Kappa

2018-06-06 zacks
International Paper Company (IP - Free Report) has decided to cancel its proposal for the takeover of the Irish packaging company — Smurfit Kappa — due to lack of engagement from the latter’s management. Memphis-based International Paper was given time until Jun 6 to make a binding offer for the buyout by the Irish Takeover Panel. The company confirmed that it has dropped its pursuit to acquire its Ireland-based rival.
SEOFF IP INPAP UFS SEOAY SEOJF

4
Domtar Rides on Solid Price Momentum & Cost Optimization

2018-06-04 zacks
On Jun 4, we issued an updated research report on, Domtar Corporation (UFS - Free Report) . The paper & paper products firm continues to benefit from strong price momentum in the Pulp and Paper businesses. Manufactured paper shipments in first-quarter 2018 were 3% higher year over year while average transaction prices for all paper grades increased $3 per ton. Average pulp prices increased $144 per metric ton from the year-ago quarter on solid global demands.
SPPJY SEOFF DB UPMKY UFS SEOAY SEOJF

 
Stora Enso Oyj 2018 Q1 - Results - Earnings Call Slides

2018-04-28 seekingalpha
The following slide deck was published by Stora Enso Oyj in conjunction with their 2018 Q1 earnings call.
SEOFF SEOAY SEOJF

 
DECISIONS OF PONSSE PLC'S ANNUAL GENERAL MEETING

2018-04-09 globenewswire
Financial statements The AGM approved the parent company financial statements and the consolidated financial statements, and members of the Board of Directors and the President and CEO were discharged from liability for the 2017 financial period.
SEOFF SEOAY SEOJF

 
PONSSE OYJ:N VARSINAISEN YHTIÖKOKOUKSEN PÄÄTÖKSIÄ

2018-04-09 globenewswire
Tilinpäätös Yhtiökokous vahvisti emoyhtiön ja konsernin tilinpäätöksen sekä myönsi hallituksen jäsenille ja toimitusjohtajalle vastuuvapauden tilikaudelta 2017.
SEOFF SEOAY SEOJF

5
Reasons Why You Should Hold WestRock in Your Portfolio Now

2018-03-28 zacks
WestRock Company (WRK - Free Report) remains well-poised for growth, backed by its focus on execution of capital allocation strategy and KapStone acquisition. Improving industry conditions and a positive volume along with pricing dynamics are other key growth drivers for the company. However, raw material cost inflation and weak demand for processed foods as well as carbonated drinks remain headwinds.
SEOFF DB VRTV SEOAY WRK SEOJF

1
Domtar Rides on Modest Revenue Growth, Margin Woes Remain

2018-03-26 zacks
On Mar 26, we issued an updated research report on paper & paper products firm, Domtar Corporation (UFS - Free Report) . Domtar is currently seeking growth through profitable investment opportunities with a commitment to pollution-free environment and sustainable practices. The company is also streamlining the cost structure, improving revenue quality and maintaining a healthy cash flow with a disciplined approach to cash utilization.
SEOFF UFS VRTV SEOAY SEOJF

 
Warmer Winters Are a Huge Threat to $30 Billion Nordic Industry - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HLMNY SEOFF SEOAY SEOJF HLHLY HLMNF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 86210M106